Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Mahtabalsadat Mirjalili, Mojtaba Shafiekhani & Afsaneh Vazin. (2020) Coronavirus Disease 2019 (COVID-19) and Transplantation: Pharmacotherapeutic Management of Immunosuppression Regimen. Therapeutics and Clinical Risk Management 16, pages 617-629.
Read now
Read now
Tommy R Tong. (2009) Therapies for coronaviruses. Part 2: inhibitors of intracellular life cycle. Expert Opinion on Therapeutic Patents 19:4, pages 415-431.
Read now
Read now
Articles from other publishers (36)
Sri Wulandari, Hartono & Tri Wibawa. (2023)
The role of
HMGB1
in
COVID‐19‐induced
cytokine storm and its potential therapeutic targets: A review
. Immunology 169:2, pages 117-131.
Crossref
Crossref
Susan M. Poutanen. 2023. Principles and Practice of Pediatric Infectious Diseases. Principles and Practice of Pediatric Infectious Diseases
1167
1175.e6
.
Dania Vázquez-Blomquist, Mónica Bequet-Romero, Yssel Mendoza-Marí, Gilda Lemos, Iris Valdés, Camila Canaán-Haden Ayala, Isabel Gonzáles Moya, Ricardo Martínez Rosales, Giselle Freyre Corrales & Gerardo Guillén-Nieto. (2022) Nasalferon, a new nasal formulation of IFNα2b, modulates cellular and molecular elements associated with an antiviral response in mucosa and blood. Clinical Immunology Communications 2, pages 39-45.
Crossref
Crossref
Helen Piontkivska, Benjamin Wales-McGrath, Michael Miyamoto & Marta L Wayne. (2021) ADAR Editing in Viruses: An Evolutionary Force to Reckon with. Genome Biology and Evolution 13:11.
Crossref
Crossref
William J. Melvin, Christopher O. Audu, Frank M. Davis, Sriganesh B. SharmaAmrita JoshiAaron DenDekkerSonya WolfEmily BarrettKevin MangumXiaofeng ZhouMonica Bame, Alex Ruan, Andrea ObiSteven L. KunkelBethany B. Moore & Katherine A. Gallagher. (2021) Coronavirus induces diabetic macrophage-mediated inflammation via SETDB2. Proceedings of the National Academy of Sciences 118:38.
Crossref
Crossref
Areej A. Malhani, Mushira A. Enani, Fatemeh Saheb Sharif-Askari, Mona R. Alghareeb, Roaa T. Bin-Brikan, Safar A. AlShahrani, Rabih Halwani & Imad M. Tleyjeh. (2021) Combination of (interferon beta-1b, lopinavir/ritonavir and ribavirin) versus favipiravir in hospitalized patients with non-critical COVID-19: A cohort study. PLOS ONE 16:6, pages e0252984.
Crossref
Crossref
George D Liatsos. (2021) Controversies’ clarification regarding ribavirin efficacy in measles and coronaviruses: Comprehensive therapeutic approach strictly tailored to COVID-19 disease stages. World Journal of Clinical Cases 9:19, pages 5135-5178.
Crossref
Crossref
Alessandra Bartoli, Filippo Gabrielli, Tatiana Alicandro, Fabio Nascimbeni & Pietro Andreone. (2021) COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs. Internal and Emergency Medicine 16:2, pages 281-308.
Crossref
Crossref
Tianguang Huang, Lin Sun, Dongwei Kang, Vasanthanathan Poongavanam, Xinyong Liu, Peng Zhan & Luis Menéndez-Arias. 2021. Antiviral Drug Discovery and Development. Antiviral Drug Discovery and Development
219
260
.
Chao Quan, Caiyan Li, Han Ma, Yisha Li & Huali Zhang. (2020) Immunopathogenesis of Coronavirus-Induced Acute Respiratory Distress Syndrome (ARDS): Potential Infection-Associated Hemophagocytic Lymphohistiocytosis. Clinical Microbiology Reviews 34:1.
Crossref
Crossref
Yinan Xiao, Hanyue Xu, Wen Guo, Yunuo Zhao, Yuling Luo, Ming Wang, Zhiyao He, Zhenyu Ding, Jiyan Liu, Lei Deng, Fushen Sha & Xuelei Ma. (2020) Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines. Molecular Biomedicine 1:1.
Crossref
Crossref
Liujing Qu, Jinchun Li & Hao Ren. (2020) COVID-19: the epidemiology and treatment. British Journal of Hospital Medicine 81:10, pages 1-9.
Crossref
Crossref
Marcin F. Osuchowski, Federico Aletti, Jean-Marc Cavaillon, Stefanie B. Flohé, Evangelos J. Giamarellos-Bourboulis, Markus Huber-Lang, Borna Relja, Tomasz Skirecki, Andrea Szabó & Marc Maegele. (2020) SARS-CoV-2/COVID-19: Evolving Reality, Global Response, Knowledge Gaps, and Opportunities. Shock 54:4, pages 416-437.
Crossref
Crossref
Shao-rui Hao, Ren Yan, Shan-yan Zhang, Jiang-shan Lian, Huan Cai, Xiao-li Zhang, Lin Zheng, Hong-yu Jia, Jian-hua Hu, Guo-dong Yu, Jue-qing Gu, Chan-yuan Ye, Ci-liang Jin, Ying-feng Lu, Jiao-jiao Xin, Ji-fang Sheng & Yi-da Yang. (2020) Interferon-α2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients: a preliminary matched case-control study干扰素-α2b 喷雾吸入未缩短住院患者的 SARSCoV-2 的脱落时间: 一项初步的配对病例对照研究. Journal of Zhejiang University-SCIENCE B 21:8, pages 628-636.
Crossref
Crossref
Yang Song, Min Zhang, Ling Yin, Kunkun Wang, Yiyi Zhou, Mi Zhou & Yun Lu. (2020) COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2). International Journal of Antimicrobial Agents 56:2, pages 106080.
Crossref
Crossref
Hatem A. Elshabrawy. (2020) SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries. Vaccines 8:2, pages 335.
Crossref
Crossref
Susan M. Poutanen. 2018. Principles and Practice of Pediatric Infectious Diseases. Principles and Practice of Pediatric Infectious Diseases
1148
1152.e3
.
Qingzhan Zhang, Jinyou Ma & Dongwan Yoo. (2017) Inhibition of NF-κB activity by the porcine epidemic diarrhea virus nonstructural protein 1 for innate immune evasion. Virology 510, pages 111-126.
Crossref
Crossref
Qingzhan Zhang, Kaichuang Shi & Dongwan Yoo. (2016) Suppression of type I interferon production by porcine epidemic diarrhea virus and degradation of CREB-binding protein by nsp1. Virology 489, pages 252-268.
Crossref
Crossref
Ali S. Omrani & Ziad A. Memish. (2015) Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection: How Close Are We?. Current Treatment Options in Infectious Diseases 7:3, pages 202-216.
Crossref
Crossref
Chong-Shan Shi, Hai-Yan Qi, Cedric Boularan, Ning-Na Huang, Mones Abu-Asab, James H. Shelhamer & John H. Kehrl. (2014) SARS-Coronavirus Open Reading Frame-9b Suppresses Innate Immunity by Targeting Mitochondria and the MAVS/TRAF3/TRAF6 Signalosome. The Journal of Immunology 193:6, pages 3080-3089.
Crossref
Crossref
Susan M. Poutanen. 2012. Principles and Practice of Pediatric Infectious Diseases. Principles and Practice of Pediatric Infectious Diseases
1117
1120.e4
.
Stuart G. Siddell, John Ziebuhr & Eric J. Snijder. 2010. Topley & Wilson's Microbiology and Microbial Infections. Topley & Wilson's Microbiology and Microbial Infections.
W. Garrett Nichols, Angela J. Peck Campbell & Michael Boeckh. (2008) Respiratory Viruses Other than Influenza Virus: Impact and Therapeutic Advances. Clinical Microbiology Reviews 21:2, pages 274-290.
Crossref
Crossref
Susan M. Poutanen. 2008. Principles and Practice of Pediatric Infectious Disease. Principles and Practice of Pediatric Infectious Disease
1101
1104
.
Jun ChenKanta Subbarao. (2007) The Immunobiology of SARS. Annual Review of Immunology 25:1, pages 443-472.
Crossref
Crossref
Luisa Cervantes-BarraganRoland ZüstFriedemann WeberMartin SpiegelKarl S. LangShizuo Akira, Volker ThielBurkhard Ludewig. (2006) Control of coronavirus infection through plasmacytoid dendritic-cell–derived type I interferon. Blood 109:3, pages 1131-1137.
Crossref
Crossref
Carolina Scagnolari, Simona Trombetti, Alessia Alberelli, Simona Cicetti, Daniela Bellarosa, Roberta Longo, Alberto Spanò, Elisabetta Riva, Massimo Clementi & Guido Antonelli. (2007) The Synergistic Interaction of Interferon Types I and II Leads to Marked Reduction in Severe Acute Respiratory Syndrome-Associated Coronavirus Replication and Increase in the Expression of mRNAs for Interferon-Induced Proteins. Intervirology 50:2, pages 156-160.
Crossref
Crossref
Martin Spiegel & Friedemann Weber. (2006) Inhibition of cytokine gene expression and induction of chemokine genes in non-lymphatic cells infected with SARS coronavirus. Virology Journal 3:1.
Crossref
Crossref
Joshua Fink, Feng Gu & Subhash G. Vasudevan. (2006) Role of T cells, cytokines and antibody in dengue fever and dengue haemorrhagic fever. Reviews in Medical Virology 16:4, pages 263-275.
Crossref
Crossref
Ken Alibek & Ge Liu. (2006) Biodefense Shield and Avian Influenza. Emerging Infectious Diseases 12:5, pages 873-875.
Crossref
Crossref
Tamaki Okabayashi, Hiroaki Kariwa, Shin-ichi Yokota, Shigeo Iki, Tomokazu Indoh, Noriko Yokosawa, Ikuo Takashima, Hiroyuki Tsutsumi & Nobuhiro Fujii. (2006) Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections. Journal of Medical Virology 78:4, pages 417-424.
Crossref
Crossref
Jan Balzarini, Els Keyaerts, Leen Vijgen, Frank Vandermeer, Miguel Stevens, Erik De Clercq, Herman Egberink & Marc Van Ranst. (2006) Pyridine N-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture. Journal of Antimicrobial Chemotherapy 57:3, pages 472-481.
Crossref
Crossref
D GRONEBERG, S POUTANEN, D LOW, H LODE, T WELTE & P ZABEL. (2005) Treatment and vaccines for severe acute respiratory syndrome. The Lancet Infectious Diseases 5:3, pages 147-155.
Crossref
Crossref
Birgit Morgenstern, Martin Michaelis, Patrick C. Baer, Hans W. Doerr & Jindrich CinatlJr.Jr.. (2005) Ribavirin and interferon-? synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochemical and Biophysical Research Communications 326:4, pages 905-908.
Crossref
Crossref
Els Keyaerts, Leen Vijgen, Piet Maes, Johan Neyts & Marc Van Ranst. (2004) In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochemical and Biophysical Research Communications 323:1, pages 264-268.
Crossref
Crossref